A Multi-center, Prospective, Randomized Study With PriMatrix and PriMatrix Ag for the Treatment of Venous Leg Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
TEI Biosciences Inc.
ClinicalTrials.gov Identifier:
NCT01612806
First received: June 4, 2012
Last updated: February 21, 2013
Last verified: February 2013
  Purpose

To evaluate the effectiveness of PriMatrix, PriMatrix Ag, and Standard of Care in the treatment of venous leg ulcers (VLUs).


Condition Intervention
Venous Stasis Ulcer
Device: PriMatrix
Device: PriMatrix Ag
Procedure: moist wound therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-center, Prospective, Randomized Study With PriMatrix Dermal Repair Scaffold, PriMatrix Ag Antimicrobial Dermal Repair Scaffold, and Standard of Care for the Treatment of Venous Leg Ulcers

Resource links provided by NLM:


Further study details as provided by TEI Biosciences Inc.:

Primary Outcome Measures:
  • Percent of VLUs healed by week 12 post-randomization [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cost of treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 31
Study Start Date: June 2011
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PriMatrix
PriMatrix Dermal Repair Scaffold
Device: PriMatrix Procedure: moist wound therapy
Experimental: PriMatrix Ag
PriMatrix Ag Antimicrobial Dermal Repair Scaffold
Device: PriMatrix Ag Procedure: moist wound therapy
Active Comparator: Standard of Care
Standard of Care Moist Wound Therapy
Procedure: moist wound therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women ≥ 18 years of age
  • Ankle-brachial index (ABI) > 0.80
  • Study wound 2-64 cm2 surface area
  • Wound does not exhibit a greater than 50% reduction in surface area during the screening period

Exclusion Criteria:

  • Suspected or confirmed signs/symptoms of wound infection
  • Hypersensitivity to bovine collagen
  • Body Mass Index (BMI) ≥ 45
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01612806

Locations
Puerto Rico
Caribbean Clinical Trials
Hato Rey, Puerto Rico
Dr. Pila Metropolitan Hospital Wound Healing Center
Ponce, Puerto Rico
Doctors' Center Hospital of San Juan
San Juan, Puerto Rico
Wound and Ulcer Care Clinic of San Juan
San Juan, Puerto Rico
Wilma N. Vazquez Hospital
Vega Baja, Puerto Rico
Sponsors and Collaborators
TEI Biosciences Inc.
  More Information

No publications provided

Responsible Party: TEI Biosciences Inc.
ClinicalTrials.gov Identifier: NCT01612806     History of Changes
Other Study ID Numbers: TEI-006
Study First Received: June 4, 2012
Last Updated: February 21, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Leg Ulcer
Postphlebitic Syndrome
Postthrombotic Syndrome
Varicose Ulcer
Ulcer
Skin Ulcer
Skin Diseases
Phlebitis
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases
Venous Insufficiency
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Varicose Veins
Pathologic Processes
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014